0.1524
전일 마감가:
$0.21
열려 있는:
$0.145
하루 거래량:
11,517
Relative Volume:
66.00
시가총액:
$N/A
수익:
-
순이익/손실:
$-16.08M
주가수익비율:
-0.00443
EPS:
-34.43
순현금흐름:
$-11.54M
1주 성능:
-21.52%
1개월 성능:
-80.61%
6개월 성능:
-86.27%
1년 성능:
-97.18%
Bio Path Holdings Inc Stock (BPTH) Company Profile
BPTH을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
BPTH
Bio Path Holdings Inc
|
0.1524 | 0 | 0 | -16.08M | -11.54M | -34.43 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Bio Path Holdings Inc Stock (BPTH) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2021-03-11 | 개시 | ROTH Capital | Buy |
2017-11-13 | 재확인 | H.C. Wainwright | Buy |
2016-08-10 | 재확인 | Maxim Group | Buy |
2016-04-18 | 개시 | Rodman & Renshaw | Buy |
2014-06-02 | 재개 | Maxim Group | Buy |
2014-05-09 | 개시 | Maxim Group | Buy |
모두보기
Bio Path Holdings Inc 주식(BPTH)의 최신 뉴스
Bio-Path Holdings, Inc. (NASDAQ:BPTH) Short Interest Update - Defense World
Tevogen Bio Holdings Inc. stock trend outlook and recovery pathFree Long Hold Safe Return Strategy - Newser
Adicet Bio Inc. stock trend outlook and recovery pathLow Risk Picks for Daily Trading Released - metal.it
Cutaneous T-Cell Lymphoma Pipeline Outlook Report 2025: Key 25+ Companies and Breakthrough Therapies Shaping the Future Landscape - The Globe and Mail
TOPAZ REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS DEMONSTRATING STRONG ROYALTY AND INFRASTRUCTURE GROWTH - The Globe and Mail
Cutaneous T-Cell Lymphoma Pipeline Outlook Report 2025: Key 25+ Companies And Breakthrough Therapies Shaping The Future Landscape - Menafn.com
Antisense & RNAi Therapeutics Market Outlook 2025-2033: - GlobeNewswire
The Zacks Analyst Blog Highlights Meta Platforms, Alphabet, Microsoft and Tesla - The Globe and Mail
Antisense & RNAi Therapeutics Market Outlook 2025-2033: Advancements in Drug Delivery Propel Growth with Revenues Forecast to Reach $3.3 Billion by 2033 - Yahoo Finance
Tucows Announces Timing for Q2 2025 Financial Results News Release and Management Commentary - The Globe and Mail
Meta Platforms Is Helping Power This 6%-Yielding Dividend Stock's Continued Growth - The Globe and Mail
Google's AI push pays off with solid second quarter, but doubts about company's future persist - The Globe and Mail
Tevogen Bio Holdings Inc. Stock Analysis and ForecastFree Daily Trading Room Entry - Autocar Professional
What analysts say about Tevogen Bio Holdings Inc. stockFree Predictions - jammulinksnews.com
Cutaneous T-cell Lymphoma Market Anticipates Impressive - GlobeNewswire
Cutaneous T-cell Lymphoma Market Anticipates Impressive Growth Trajectory at a CAGR of 7.1% During the Study Period (2020–2034) | DelveInsight - GlobeNewswire
Cutaneous T-cell lymphoma Clinical Trials 2025: EMA, PDMA, FDA - openPR.com
Cutaneous T-cell lymphoma Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight - Barchart.com
Freeport-McMoRan to Post Q2 Earnings: What's in Store for the Stock? - The Globe and Mail
What drives Tevogen Bio Holdings Inc. stock priceFree Stock Selection - printweek.in
Carvana Is Up 100x Since the 2022 Lows. Could This Stock Be Next? - The Globe and Mail
Mullen Announces Plan to Change Company’s Name to Bollinger Innovations, Inc. and NASDAQ Approval for New Symbol — BINI - The Globe and Mail
Antisense Oligonucleotide Therapeutics Pipeline Appears - openPR.com
Antisense Oligonucleotide Therapeutics Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Barchart.com
Menin Inhibitors Market Forecasts Signal Strong Uptake of Menin Inhibitors in Hematologic Oncology Across the 7MM During the Forecast Period (2020-2034) | DelveInsight - PR Newswire UK
Antisense Oligonucleotide Therapeutics Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working In The Therapeutics Segment Delveinsight - Menafn.com
Oligonucleotides Competitive Landscape 2025: 320+ Therapies - openPR.com
Waldenstrom Macroglobulinemia Market Sees Surging Demand - GlobeNewswire
Waldenstrom Macroglobulinemia Market Sees Surging Demand Across the 7MM Amid BTK Inhibitor Advancements | DelveInsight - Business Upturn
Massive $888M Deal: Biotech Firm Makes Historic Pivot to Become Largest US Public HYPE Token Holder - Stock Titan
Where Will Arista Networks Be in 5 Years? - The Globe and Mail
30 Billion Reasons to Buy Oracle Stock Like There's No Tomorrow - The Globe and Mail
Top 5 AI Growth Stocks to Buy in July 2025 - The Globe and Mail
Delisting of Securities from The Nasdaq Stock Market - The Manila Times
Bio-Path Holdings announces executive resignations and operational pause - Investing.com
Bio-Path Holdings Faces Leadership Changes and Operational Pause, Considers Strategies Amid Limited Capital - AInvest
Bio-Path Holdings Faces Leadership Changes and Operational Pause - TipRanks
Cutaneous T Cell Lymphoma Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Barchart.com
Oligonucleotides Clinical Trial Pipeline Analysis Demonstrates 280+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - SINA HONG KONG LIMITED
Life Sciences Investor Forum: Now Available for Online Viewing - The Manila Times
GitLab (NASDAQ:GTLB) Given New $60.00 Price Target at Wells Fargo & Company - Defense World
GRI Bio’s (GRI) Buy Rating Reaffirmed at HC Wainwright - Defense World
Short Interest in Bitcoin Depot Inc. (NASDAQ:BTMWW) Expands By 5,350.0% - Defense World
GitLab (NASDAQ:GTLB) Price Target Cut to $52.00 by Analysts at JPMorgan Chase & Co. - Defense World
Bio-Path Holdings, Inc. (NASDAQ:BPTH) Short Interest Up 870.6% in May - Defense World
Two Sigma Investments LP Cuts Position in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) - Defense World
Two Sigma Investments LP Reduces Stock Holdings in Industrial Logistics Properties Trust (NASDAQ:ILPT) - Defense World
Two Sigma Investments LP Makes New $273,000 Investment in ORIX Co. (NYSE:IX) - Defense World
Is Howmet Aerospace Stock Outperforming the S&P 500? - The Globe and Mail
Life Sciences Investor Forum Agenda Announced for June 11th-12th - GlobeNewswire
Bio-Path Holdings to Present at Life Sciences Virtual Investor F - GuruFocus
Bio Path Holdings Inc (BPTH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):